




DOI 10.4070 / kcj.2009.39.10.393 
Print ISSN 1738-5520 / On-line ISSN 1738-5555
Copyright ⓒ 2009 The Korean Society of Cardiology
Open Access   
The Inflammatory Response and Cardiac Repair   
After Myocardial Infarction 
 
Deuk-Young Nah, MD and Moo-Yong Rhee, MD 
Division of Cardiology, Department of Internal Medicine, College of Medicine, Dongguk University, Gyeongju, Korea 
 
ABSTRACT 
One of the most important therapeutic targets of current cardiology practice is to determine optimal strategies for 
the minimization of myocardial necrosis and optimization of cardiac repair following an acute myocardial infarc-
tion. Myocardial necrosis after acute myocardial infarction induces complement activation and free radical gene-
ration, triggering a cytokine cascade initiated by tumor necrosis factor-alpha (TNF-α) release. When reperfusion of 
the infarcted area is initiated, intense inflammation follows. Chemokines, cytokines and the complement system 
play an important role in recruiting neutrophils in the ischemic and reperfused myocardium. Cytokines promote 
adhesive interactions between leukocytes and endothelial cells, resulting in transmigration of inflammatory cells 
into the site of injury. The recruited neutrophils have potent cytotoxic effects through the release of proteolytic 
enzymes, and they interact with adhesion molecules on cardiomyocytes. In spite of the potential injury, reperfusion 
enhances cardiac repair; this may be related to the inflammatory response. Monocyte chemoattractant protein 
(MCP)-1 is upregulated in reperfused myocardium and can induce monocyte recruitment in the infarcted area. 
Monocyte subsets play a role in phagocytosis of dead cardiomyocytes and in granulation tissue formation. In ad-
dition, the transforming growth factor (TGF)-β plays a crucial role in cardiac repair by suppressing inflam-
mation. Resolution of inflammatory infiltration, containment of inflammation and the reparative response af-
fecting the infarcted area are essential for optimal infarct healing. Here, we review the current literature on the 
inflammatory response and cardiac repair after myocardial infarction. (Korean Circ J 2009;39:393-398) 
 





Acute myocardial infarction is a potentially fatal event 
and a common causes of death in adults. Sudden coro-
nary artery occlusion results in ischemic related death of 
cardiomyocytes.
1) The human heart has low regenerative 
ability. The inflammatory response and cytokine release 
from the myocardium are essential components of the 
host response to acute myocardial infarction, and play a 
crucial role in cardiac repair. Tumor necrosis factor-alpha 
(TNF-α) and interleukin-6 (IL-6) are increased after an 
acute myocardial infarction and can regulate myocyte 
survival and induce additional cellular inflammatory re-
sponses.
2)3) Chemokines stimulate the recruitment of in-
flammatory leukocytes to the infarct related myocar-
dium.
4) Monocyte chemoattractant protein (MCP-I)/ 
CCL2 has a potent effect on macrophage recruitment 
and myofibroblast accumulation in healing myocardium 
and also plays an important role in postinfarct left ven-
tricular healing.
5) Transforming growth factor (TGF)-β 
also plays a crucial role in cardiac repair by the suppres-
sion of inflammation.
6) Timely resolution of the inflam-
mation and inhibition of the inflammatory response 
and recovery from tissue injury of the infarcted area are 
essential for optimal healing of the myocardium. Here 
we review recent researches and evolving concepts of the 
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(ROS) and cytokine cascade mediated pathway play an 
important role in the post infarction inflammatory re-
sponse. 
 
Complement cascade activation 
Hill and Ward were the first to report that ischemic 
myocardial injury can induce activation of the comple-
ment cascade in a rat infarct model.
7) Pinckard et al.
8) 
also showed that ischemic myocardial necrosis was as-
sociated with the release of subcellular membrane cons-
tituents that are triggered by the early acting components 
of the complement cascade (C1, C4, C2 and C3) in pa-
tients with an acute myocardial infarction. Yasojima et 
al.
9) demonstrated that complement gene expression was 
upregulated by ischemia and reperfusion in the rabbit 
heart. Complement activation was reported to induce 
neutrophil and monocyte recruitment in the ischemic 
myocardium.
10) Weisman et al.
11) reported that infusion 
of soluble human complement receptor type 1 (sCR1) 
significantly suppressed post-infarct inflammation and 
necrosis in a rat model of myocardial ischemia and 
reperfusion. In spite of promising experimental results, 
recent clinical trials testing the effects of complement 
inhibition, in patients with acute myocardial infarction, 
showed disappointing results. Administration of the 
human anti-C5 monoclonal antibody pexelizumab, in 
patients with an acute myocardial infarction, had no 
effect on infarct size and clinical outcome.
12-14) 
 
Reactive oxygen species 
Meldrum et al.
15) demonstrated that H2O2 alone in-
duced myocardial TNF-α mediated cardiac injury by a 
p38 mitogen-activated protein kinase (MAPK)-depen-
dent mechanism. Reactive oxygen intermediates may 
generate a leukotatic stimulus that includes, comple-
ment activation, induction of hemorrhagic shock-in-
duced P-selectin expression, chemokine upregulation 
and an increase in the endothelial intercellular adhe-
sion molecule (ICAM)-1 ability to bind neutrophils.
16-19) 
The use of the antioxidant enzymes superoxide dismutase 
and catalase reduced the infarct size in dogs with myo-
cardial ischemia and reperfusion.
20) However, there have 
been some failed studies of antioxidant treatment used 
to prevent myocardial ischemic injury.
21)22) Two clinical 
studies using recombinant human superoxide dismutase 
in patients with an acute myocardial infarction undergo-
ing percutaneous coronary intervention or thrombolysis 





Cytokines can self-amplify through a positive feed-
back loop targeting the nuclear factor (NF)-κB. Upre-
gulation of TNF-α in the infarct myocardium can 
upregulate the levels of TNF-α in the neighboring nor-
mal myocardium, leading to amplified cytokine effects.
3) 
TNF-α stimulates expression of proinflammatory cy-
tokines, chemokines and adhesion molecules by leuko-
cytes and endothelial cells and regulates extracellular 
matrix metabolism by reducing collagen synthesis and 
by enhancing matrix metalloprotease (MMP) activity in 
cardiac fibroblasts;25) other adhesive cytokines such as 
monocyte chemoattractant protein (MCP)-1 is also in-
duced in the ischemic and reperfused canine myocardi-
um. Kumar et al.
26) suggested a significant role for MCP-
1 in monocyte trafficking in reperfused myocardium. 
 
Cytokine and chemokine upregulation 
Chemokine upregulation is a noted feature of the post-
infarction inflammatory response (Table 1).
27) Recent 
investigators have demonstrated strong induction of sev-
eral chemokines in the ischemic myocardium supporting 
their role in leukocyte recruitment.
4) MCP-1 upregula-
tion has been demonstrated in a mouse model.
28) Fran-
gogiannis reported that a MCP-1 -/- infarct mouse mo-
del had decreased mesenger ribonucleic acid (mRNA) 
expression of the cytokine TNF-α, IL-1β, TGF-β 
and IL-10 and showed defective macrophage differentia-
tion.
27) Induction and release of cytokines such as TNF-
α and  IL-6 are rapidly released in the central zone dur-
ing a myocardial infarction; however, they are usually 
maximal in the border zone.
3)29) This robust upregulation 
may return to baseline levels if the infarction is small, 
and if the infarction is large and the inflammatory re-
sponse is excessive, there can be sustained cytokine up-
regulation, corresponding to a chronic remodeling phase. 
 




Neutrophils are recruited during the initial stage of 
cardiac ischemic injury. Neutrophil transmigration in the 
infarcted myocardium requires adhesive interactions with 
Table 1. Upregulated chemokines and their role after myocardial ischemia and reperfusion
CXCL8/Interleukin (IL)-8  Induce neutrophil infiltration 
CCL2/Monocyte Chemoattractant Protein (MCP)-1  Regulate monocyte and lymphocyte recruitment
CCL3/Macrophage Inflallatroy Protein (MIP)-1α   Regulate monocyte and lymphocyte recruitment
CCL4/Macrophage Inflallatroy Protein (MIP)-1β   Regulate monocyte and lymphocyte recruitment
CXCL10/Interferon-10  Angiostatic factor with antifibrotic properties  
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activated vascular endothelial cells. Neutrophils may se-
crete oxidants and proteases and possibly express media-
tors capable of amplifying cell recruitment.
30) Neutrophil 
depletion in animals undergoing reperfused myocardial 
infarction has been reported to significantly decrease the 
infarct size suggesting that a significant amount of myo-
cardial injury may be induced by neutrophil dependent 
mechanisms.
31)32) 
However, the mechanisms associated with neutrophil-
induced myocardial ischemic injury have not been iden-
tified. Jaeschke et al.
33) suggested that neutrophils may di-
rectly injure parenchymal cells through release of specific 
toxic products. The selectin family consists of L-selectin, 
P-selectin and E-selectin. P-selectin expression occurs 
rapidly in endothelial cells during cardiac ischemic in-
jury. Experimental study has suggested that monoclonal 
antibodies against P-selectin reduced myocardial necrosis, 
preserving coronary endothelial function and attenuat-
ing neutrophil infiltration in ischemic and reperfused 
myocardium.
34) However, there have been inconsistent 
results of selectin-related interventions in experimental 
models of myocardial ischemia.
35)36) 
 
The mononuclear cells 
As previously mentioned, MCP-1/CCL2 plays an im-
portant role in monocyte recruitment to the infarcted 
myocardium.
5) Cytokines, such as TGF-β, free radical 
oxygen, complement, and the CC chemokine may also 
play a role in monocyte infiltration. Infiltration of mo-
nocytes into the infarcted myocardium is followed by 
maturation and differentiation of these blood-derived 
cells into macrophages. 
 
Cardiac Repair After  
Myocardial Infaction 
 
Healing of an infarction can be divided into three 
overlapping phases: the inflammatory phase, the proli-
ferative phase and the maturation phase (Fig. 1).
37) The 
acute repair process is mediated by cytokines and inflam-
matory cells in the infarcted myocardium. The induction 
of pro-inflammatory mediators and leukocyte infiltra-
tion play a crucial role in phagocytosis and removal of 
necrotic cells and matrix debris from infarcted myocar-
dium. Moreover, they promote tissue repair and scar for-
mation.
38) The strategy for optimal infarct healing re-
quires inhibition of cytokines and chemokine synthesis 
after myocardial infarction. 
 
Transforming growth factor-β  as a key regulator 
in cardiac repair 
TGF-β is a multifunctional cytokine that controls 
proliferation and cellular differentiation in most cells. 
TGF-β has been shown to be significantly upregulated 
in an experimental rat model of myocardial infarction; 
in addition, TGF-β mRNA and protein was signifi-
cantly increased at the infarct border zone.
39)40) During 
infarct healing, TGF-β may play a role in the suppres-
sion of chemokine and cytokine synthesis and is thought 
to be a key mediator of the transition from inflamma-
tion to fibrosis.
41) Lefer et al.
42) reported that TGF-β in-
jections reduced myocardial ischemic injury mediated 
by proinflammatory cytokines such as TNF-α during 
the inflammatory phase of myocardial healing. Anti-
TGF-β treatment before or after coronary artery liga-
tion increased mortality and worsened the left ventricular 
remodeling in mice with non-reperfused myocardial in-
farction.
43) The inhibition of TGF-β signaling by in-
jection of a TGF-β  II receptor resulted in reduction of 
left ventricular remodeling by modulation of cardiac 
fibrosis; early TGF-β inhibition increased mortality and 
left ventricular dilatation.
44)45) Youn et al.
46) reported that 
the angiotensin converting enzyme inhibitor and angio-
tensin receptor blockade resulted in decreased TGF-β 
mRNA expression after nontransmural infarction in the 
rat. 
However, the exact role of TGF-β signaling in the in-
farcted and remodeled heart is poorly understood con-
sidering the complex and unusual biology of TGF-β 
(Table 2).
47) 
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The role of other cytokines in cardiac repair 
There are three IL-1 molecules consisting of IL-1α, 
IL-β and IL-1 Ra that are specific receptor antago-
nists.
48) Bujak et al.
49) demonstrated that IL-1 signaling 
is essential for activation of inflammatory and fibrogenic 
pathways in the healing infarct and plays an important 
role in the pathogenesis of remodeling after infarction. 
IL-10 exerts potent anti-inflammatory effects and modu-
lates MMP expression.
50-52) However, Zymek et al.
53) and 
our group reported that IL-10 signaling plays a non-
critical role in the suppression of inflammatory media-
tors, resolution of the inflammatory response and fibrous 
tissue deposition following myocardial infarction in the 
mouse. This result may be due to the involvement of 
multiple overlapping regulatory mechanisms controll-
ing various proinflammatory pathways activated in the 
infarcted myocardium. 
 
The role of proteins in cardiac repair 
CD44 is a cell surface glycoprotein involved in cell-
cell interaction and cell adhesion and migration. CD44-
hyaluronan interactions play a role in leukocyte extrav-
asation at the inflammatory site and serves as a key 
factor in the resolution of inflammation through removal 
of matrix breakdown products and clearance of apoptotic 
neutrophils.
54-56) Huebener et al.
57) tested the role of 
CD44 in infarct healing and demonstrated that CD44 
mRNA levels were significantly induced in the infarcted 
heart; CD44 null mice showed enhanced and prolong-
ed inflammation in the infarcted heart followed by 
decreased myofibroblast infiltration, reduced collagen 
deposition and diminished proliferative activity. Hue-
bener et al.
57) concluded that CD44 is critically involved 
in infarct healing by regulating the inflammatory and 
fibrotic response. Thrombospondin (TSP)-1 is an adhe-
sive glycoprotein involved in cell to cell and cell to ma-
trix interaction with potent angiostatic properties; it is a 
TGF-β activator.
58) TSP-1 showed strikingly selective 
localization in the infarct border zone, and TSP-1 knock-
out animals had markedly increased macrophage and 
myofibroblast density in the infarct and in remodeling 
of noninfarcted myocardial areas, and was more exten-
sive in the postinfarction remodeling than in the wild-
type mice. Frangogiannis et al.
59) concluded that the 
selective endogenous expression of TSP-1 at the infarct 
border zone may serve as a “barrier,” limiting expansion 
of granulation tissue and protecting the noninfarcted 
myocardium from fibrotic remodeling. Smad is an es-
sential protein component of the TGF-β pathway.
60) 
Hao et al.
61) showed that TGF-β mRNA was signifi-
cantly increased in the infarct scar compared to viable 
myocardium, and that Cardiac Smad 2, 3 and 4 pro-
teins were significantly increased in the border and scar 
tissues when compared to viable myocardium. These re-
sults indicate that TGF-beta/Smad signaling may be 
involved in the remodeling of the infarct scar. Optimal 
cardiac repair requires containment of the inflamma-
tion in the infarcted area. Extension of the inflamma-
tion into the non-infarcted area could result in expan-
sion of the neutrophil infiltration and worsening of the 
remodeling. Currently, investigators are testing potential 
treatment strategies for prevention of the expansion of 




The inflammatory response and cytokines such as 
TNF-α and IL-6 are integral components of the host 
response to tissue injury and play an important role 
after acute myocardial infarction. Furthermore, TGF-β 
plays an important role in cardiac repair after myocardial 
infarction. Many experimental studies have shown a 
dramatic reduction in infarct size with the use of anti-
inflammatory treatment and inhibition of cytokine 
signaling. However, treatment with specific cytokine in-
hibitors has been unsuccessful in clinical practice; ex-
planations include: the animal models have fundamen-
tal differences compared to the human disease process 
and the inflammatory cascade is a complex network of 
multiple overlapping regulatory mechanisms that controls 
various pro-inflammatory pathways. The properties of 
cytokines in the network include redundancy, pleiotropy, 
synergistic activity, and the antagonistic effects on each 
other. We are now only beginning to elucidate the roles 
and significance of various cytokines and growth factors 
in healing of a myocardial infarction.   
If we get the knowledge of inflammatory response to 
ischemic myocardial injury and role of cytokines after 
myocardial infarction, the effective inflammation-relat-
ed interventions may allow us to promote improved heal-
ing and cardiac remodeling after myocardial infarction. 
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